Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 8.09
- Piotroski Score 4.00
- Grade Buy
- Symbol (CRSP)
- Company CRISPR Therapeutics AG
- Price $51.85
- Changes Percentage (-0.06%)
- Change -$0.03
- Day Low $50.60
- Day High $52.52
- Year High $91.10
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $89.50
- High Stock Price Target $180.00
- Low Stock Price Target $52.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.70
- Trailing P/E Ratio -21.43
- Forward P/E Ratio -21.43
- P/E Growth -21.43
- Net Income $-153,610,000
Income Statement
Quarterly
Annual
Latest News of CRSP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is CRISPR Therapeutics (CRSP) a Promising Gene Editing Stock?
We recently listed the 10 Most Promising Gene Editing Stocks, including CRISPR Therapeutics AG. The pharmaceutical industry is driven by innovation in gene therapy and editing, with CRISPR technology ...
By Yahoo! Finance | 1 week ago -
Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds?
Insider Monkey analyzed the most promising biotech stocks favored by hedge funds, with CRISPR Therapeutics AG (NASDAQ:CRSP) ranking among the top. Despite volatility, biotech's growth is driven by fac...
By Yahoo! Finance | 3 weeks ago -
CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers
The article discusses ARK stocks and Cathie Wood's investment approach, focusing on disruptive innovation. It highlights CRISPR Therapeutics AG (NASDAQ:CRSP) and its potential in the gene sequencing i...
By Yahoo! Finance | 1 month ago
